Patient and treatment heterogeneity were characterized within a sample of nonadherent buprenorphine members; an improved understanding of these factors may optimize patient—treatment matching and ...
Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC). Phase 3 study of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback